Lupin set to gain market share in US flu season; shares up 6% in 2 sessions

The stock has underperformed peers and the benchmark over the past year

The stock of Lupin is up over 6 per cent in the last couple of trading sessions on expectations that the demand surge in anti-viral drugs in the US market and market share gains could reflect in robust sales growth in the near term.

Mitesh Shah and Bhavya Sanghavi of Nirmal Bang Research highlight that the onset of a strong flu season in the US has led to a uptick in volumes -- in both the capsule as we as oral suspensions of oseltamivir (generic version of Tamiflu) -- used in treating influenza.

While capsules, which account for 70 per